Immune-mediated inflammatory disorders (I.M.I.D.s): The economic and clinical costs

American Journal of Managed Care

Volumn 8, Issue 21 SUPPL., 2002, Pages

  Williams, John P ^a   Meyers, Jonathan A ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ABX INTERLEUKIN 8 MONOCLONAL ANTIBODY; ADALIMUMAB; AMG 714; AZATHIOPRINE; BASILIXIMAB; CERTOLIZUMAB PEGOL; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTOKINE; DACLIZUMAB; ETANERCEPT; GAMMA INTERFERON ANTIBODY; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 15 ANTIBODY; INTERLEUKIN 2; J 695; LEFLUNOMIDE; MEPREDNISONE; METELIMUMAB; METHOTREXATE; MONOCLONAL ANTIBODY; PLACEBO; PREDNISONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SMART; TACROLIMUS; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG;

ACUTE DISEASE; ANTIINFLAMMATORY ACTIVITY; CHRONIC INFLAMMATION; CLINICAL TRIAL; CONSULTATION; COST OF ILLNESS; CROHN DISEASE; DISEASE SEVERITY; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG TARGETING; EMPLOYER; EPIDEMIOLOGICAL DATA; HEALTH CARE COST; HEALTH ECONOMICS; HEALTH INSURANCE; HUMAN; HYPERGLYCEMIA; HYPERTENSION; IMMUNE MEDIATED INFLAMMATORY DISORDER; IMMUNE RESPONSE; IMMUNOREGULATION; INFECTION; INFLAMMATORY DISEASE; INSULIN DEPENDENT DIABETES MELLITUS; MANAGED CARE ORGANIZATION; MORBIDITY; NONHUMAN; OSTEOPOROSIS; PATHOPHYSIOLOGY; PHARMACOLOGICAL BLOCKING; PREVALENCE; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SIDE EFFECT; SYSTEMIC LUPUS ERYTHEMATOSUS; TUBERCULOSIS; UNITED STATES; WEIGHT GAIN;

EID: 0036926809     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (153)

1. Sinha, AA, Lopez MT, McDevitt HO. Autoimmune diseases: The failure of self tolerance. Science. 1990; 248: 1380-1388.
2. Ehrlich P. Morgenroth J. In: Himmelweit F, Marquadt M, Dale HD, eds. The Collected Papers of Paul Ehrlich. London: Pergamon; 1900;205-212.
3. Song XR, Torphy TJ, Griswold DE, et al. Coming of age: Anti-cytokine therapies. Mol Interventions. 2002;2(1):36-46.
4. Davidson A, Diamond B. Autoimmune diseases. N Engl J Medicine. 2001;345:340-350.
5. O'Shea JJ, Ma A, Lipsy P. Cytokines and autoimmunity. Nat Immunol. 2002;2:37-45.
6. Ioannou Y, Isenberg DA. Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy. Arthritis Rheum. 2000;43:1431-1442.
7. Graninger WB, Smolen JS. One-year inhibition of tumor necrosis factor-alpha: A major success or a larger puzzle? Curr Opin Rheumatol. 2001;13:209-213.
8. Caspi RR. Short analytical review: IL-12 in autoimmunity. Clin Immunol Immunopathology 1998;88:4-13.
9. Kuhn R, Lohler J, Rennick D, et al. Interleukin-10-deficient mice develop chronic enterocolitis. Cell. 1993;75:263-274.
10. Gorelik L, Flavell RA. Abrogation of TGFβ signaling in T cells leads to spontaneous T cell differentiation and autoimmune disease. Immunity. 2000;12:171-181.
11. Rudge EU, Cutler AJ, Pritchard NR, Smith KG. Interleukin 4 reduces expression of inhibitory receptors on B cells and abolishes CD22 and Fcγ RII-mediated B cell suppression. J Exp Med. 2002;195:1097-1085.
12. Vermeire K, Heremans H, Vandeputte, M. et al. Accelerated collagen-induced arthritis in IFN-gamma receptor-deficient mice. J Immunol. 1997;158:5507-5513.
13. Brennan FM, Feldmann M. Cytokines in autoimmunity. Curr Opin Immunol. 1992;4:754-759.
14. Miga AJ, Noelle RJ. Costimulation in autoimmunity. In: Lahita RG ed. Textbook of the Autoimmune Diseases. Philadelphia, Pa: Lippincott Williams & Wilkins; 2002:175-184.
15. Mosmann TR, Coffman RL. TH1 and TH2 cells: Different patterns of lymphokine secretion lead to different functional properties. Ann Rev Immunol. 1989;7:145-173.
16. Romagnani S. The Th1/Th2 paradigm. Immunol Today. 1997;18;263-266.
17. Weiner HL. Induction and mechanism of action of transforming growth factor-beta-secreting Th3 regulatory cells. Immunol Rev. 2001;182:207-214.
18. Trinchieri G. Interleukin-12 and its role in the generation of TH1 cells. Immunol Today. 1993;14:335-338.
19. Rothenberg EV, Diamond RA, Pepper KA, Yang JA. IL-2 gene inducibility in T cells before T cell receptor expression changes in signaling pathways and gene expression requirements during intrathymic maturation. J Immunol. 1990;144:1614-1624.
20. Krakauer T, Vilcek J, Oppenheim JJ. Proinflammatory Cytokines: TNF and IL-1 families, chemokines, TGF-beta, and others. In: Paul WE ed. Fundamental Immunology, 4th Edition. Philadelphia, Pa: Lippincott-Raven Publishers; 1999:775-811.
21. Alcocer-Varela J, Valencia X. Cytokines in Autoimmunity. In: Lahita RG ed. Textbook of the Autoimmune Diseases. 2002:101-116.
22. Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med. 2001;344:907-916.
23. Jantti JK, Kaarela K, Belt EA, Kautiainen HJ. Incidence of severe outcome in rheumatoid arthritis during 20 years. J Rheumatol. 2002;29:688-92.
24. Bouchaud-Chabot A, Liote F. Cervical spine involvement in rheumatoid arthritis. A review. Joint Bone Spine. 2002;69:141-154.
25. Myllykangas-Luosujarvi RA, Aho K, Isomaki HA. Mortality in rheumatoid arthritis. Semin Arthritis Rheum. 1995;25:193-202.
26. Goodson N. Coronary artery disease and rheumatoid arthritis. Curr Opin Rheumatol. 2002;14:115-120.
27. Van Doornum S, McCollo G, Wicks IP. Accelerated atherosclerosis: An extraarticular feature of rheumatoid arthritis? Arthritis Rheum. 2002;46:862-873.
28. Sokka T, Pincus T. Work disability in US patients with rheumatoid arthritis of less than three years In: 2001 ACR Abstract Concurrent Session; Abstract 1011.
29. McDuffie FC. Morbidity impact of rheumatoid arthritis on society. Am J Med. 1985;78(1A):1-5.
30. Gregersen PK, Silver J, Winchester RJ. The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum. 1987;30:1205-1213.
31. Gerard HC, Wang Z, IWang GF, et al. Chromosomal DNA from a variety of bacterial species is present in synovial tissue from patients with various forms of arthritis. Arthritis Rheum. 2001;44:1689-1697.
32. Miltenburg AM, Van Laar JM, De Kuiper R, et al. T cells cloned from human rheumatoid synovial membrane functionally represent the Th1 subset. Scandinavian J Immunol. 1992:35:603-610.
33. Hopkins SJ, Meager A. Cytokines in synovial fluid: II. The presence of tumour necrosis factor and interferon. Clin Exp Immunol. 1988;73:88-92.
34. Hopkins SJ Humphreys M, Jayson MI. Cytokines in synovial fluid. I. The presence of biologically active and immunoreactive IL-1. Clin Exp Immunol. 1988;72:422-427.
35. Keffer J, Probert L, Cazlareis H, et al. Transgenic mice expressing human tumour necrosis factor: A predictive genetic model of arthritis. EMBO J. 1991;10:4025-4031.
36. Okamoto H, Yamamura M, Morita Y, et al.n The synovial expression and serum levels of interleukin-6, interleukin-11, leukemia inhibitory factor, and oncostatin M in rheumatoid arthritis. Arthritis Rheum. 1997;40:1096-1105.
37. Holt I, Cooper RG, Denton J, et al. Cytokine inter-relationships and their association with disease activity in arthritis. Br J Rheumatol. 1992;31:725-733.
38. Moore AR, Iwamura H, Larbre JP, et al. Cartilage degradation by polymorphonuclear leucocytes: In vitro assessment of the pathogenic mechanisms. Ann Rheum Dis. 1993;52:27-31.
39. Katsikis PD, CHu CQ, Brennan FM, et al. Immunoregulatory role of interleukin 10 in rheumatoid arthritis. J Exp Med. 1994;179:1517-1527.
40. Chomarat P, Vannier E, Dechanet J, et al. Balance of IL-1 receptor antagonist/IL-1 beta in rheumatoid synovium and its regulation by IL-4 and IL-10. J Immunol. 1995;154:1432-1439.
41. Isomaki P, Luukkainen R, Saario R, et al. Interleukin-10 functions as an antiinflammatory cytokine in rheumatoid synovium. Arthritis Rheum. 1996:39:386-395.
42. Ogorek CP, Fisher RS. Differentiation between Crohn's disease and ulcerative colitis. Med Clin North Am. 1994;78:1249-1258.
43. Schwartz DA, Loftus EV, Tremaine WJ, et al. The natural history of fistulizing Crohn's disease in Olmsted Country, Minnesota. Gastroenterology. 2002;122:875-880.
44. Bernstein CN, Blanchard JF, Kliewer E, Wajda A. Cancer risk in patients with inflammatory bowel disease: A population-based study. Cancer. 2001;91:854-862.
45. Kurina LM, Goldacre MJ, Yeates D, et al. Depression and anxiety in people with inflammatory bowel disease. J Epidemiol Community Health. 2001;55:716-720.
46. Vermeire S, Louis E, Rutgeerts P, et al. NOD2/CARD15 does not influence response to infliximab in Crohn's disease. Gastroenterology. 2002;123:106-111.
47. Madsen KL. Inflammatory bowel disease: Lessons from the IL-10 gene deficient mouse. Clin Invest Med. 2001;24:250-257.
48. + T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature. 1997;389:737-742.
49. Sartor RB. Cytokines in intestinal inflammation: Pathophysiological and clinical considerations. Gastroenterology. 1994;106:533-539.
50. Papadakis KA, Targan SR. Role of cytokines in the pathogenesis of inflammatory bowel disease. Annu Rev Med. 2000;51:289-298.
51. Lovesteam-Adrian M, Agardh CD, Torffvit O, et al. Diabetic retinopathy, visual acuity, and medical risk indicators: A continuous 10-year follow-up study in Type 1 diabetic patients under routine care. J Diabetes Complications. 2001;15:287-294.
52. Clark CM Jr, Lee DA. Prevention and treatment of the complications of diabetes mellitus. N Engl J Med. 1995;332:1210-1217.
53. Colhoun HM, Lee ET, Bennett PH, et al. Risk factors for renal failure: The WHO Multinational Study of Vascular Disease in Diabetes. Diabetologia. 2001;44(suppl 2):S46-S53.
54. Chaturvedi N, Stevens LK, Fuller JH, et al. Risk factors, ethnic differences and mortality associated with lower-extremity gangrene and amputation in diabetes. The WHO Multinational Study of Vascular Disease in Diabetes. Diabetologia. 2001;44(suppl 2):S65-S71.
55. Winter WE, Maclaren NK, Riley WJ, et al. Maturity-onset diabetes of youth in black Americans. N Engl J Med. 1987;316:285-291.
56. Back JF. Insulin-dependent diabetes mellitus as an autoimmune disease. Endocr Rev. 1994;15:516-542.
57. Rabinovitch A. An update on cytokines in the pathogenesis of insulin-dependent diabetes mellitus. Diabetes Metab Rev. 1998;14:129-151.
58. Shizuru JA, Taylor-Edwards C, Banks BA, et al. Immunotherapy of the nonobese diabetic mouse: Treatment with an antibody to T-helper lymphocytes. Science. 1988;24:659-662.
59. Rabinovitch A, Suarez-Pinzon WL. Cytokines and their roles in pancreatic islet β-cell destruction and insulin-dependent diabetes mellitus. Biochem Pharmacol. 1998;55:1139-1149.
60. Mandrup-Poulsen T. The role of interleukin-1 in the pathogenesis of IDDM. Diabetologia. 1996;39:1005-1029.
61. Rapoport MJ, Jaramillo A, Zipris D, et al. Interleukin 4 reverses T cell proliferative unresponsiveness and prevents the onset of diabetes in nonobese diabetic mice. J Exp Med. 1993;178:87-99.
62. Czaja AJ. Understanding the pathogenesis of autoimmune hepatitis. Am J Gastroenterol. 2001;96:1224-1231.
63. Salvarani C, Cantini F, Boiardi L, et al. Polymyalgia rheumatica and giant-cell arteritis. N Engl J Med. 2002;347:261-271.
64. Field M, Cook A, Gallagher G. Immunolocalisation of tumour necrosis factor and its receptors in temporal arteritis. Rheumatol Int. 1997;17:113-118.
65. Santamaria P. Effector lymphocytes in autoimmunity. Curr Opin Immunology. 2001;13:663-669.
66. Kouwenhoven M, Teleshova N, Ozenci V, et al. Monocytes in multiple sclerosis: Phenotype and cytokine profile. J Neuroimmunology. 2001;112:197-205.
67. De Jong BA, Schrijver HM, Huizinga TW, et al. Innate production of interleukin-10 and tumor necrosis factor affects the risk of multiple sclerosis. Ann Neurol. 2000;48:641-646.
68. Marshall BG, Wangoo A, Cook HT, et al. Increased inflammatory cytokines and new collagen formation in cutaneous tuberculosis and sarcoidosis. Thorax. 1996;51:1253-1261.
69. Newman LS, Rose CS, Maier LA. Sarcoidosis. N Engl J Med. 1997;336:1224-1234.
70. Mease PJ. Tumour necrosis factor (TNF) in psoriatic arthritis: Pathophysiology and treatment with TNF inhibitors. Ann Rheum Dis. 2002;61:298-304
71. Schopf RE, Aust H, Knop J. Treatment of psoriasis with the chimeric monoclonal antibody against tumor necrosis factor a, infliximab. J Am Acad Dermatol. 2002;46:886-891.
72. Braun J, De Keyser F, Brandt J, et al. New treatment options in spondyloarthropathies: Increasing evidence for significant efficacy of anti-tumor necrosis factor therapy. Curr Opin Rheumatol. 2001;13:245-249.
73. Mavalia C, Scalletti C, Romagnani P, et al. Type 2 helper T-cell predominance and high CD30 expression in systemic sclerosis. Am J Pathol. 1997;151:1751-1758.
74. Denton CP, Abraham DJ. Transforming growth factor-beta and connective tissue growth factor: Key cytokines in scleroderma pathogenesis. Curr Opin Rheumatol. 2001;13:505-11.
75. Boros DL. The role of cytokines in the formation of the schistosome egg granuloma. Immunobiology. 1994;191:441-450.
76. Blain H, Abdelmouttaleb I, Belmin J, et al. Arterial wall production of cytokines in giant cell arteritis: Results of a pilot study using human temporal artery cultures. J Gerontology. 2002;57A:M241-M245.
77. The International Classification of Diseases: Volume 1 - Tabular list. Available at: http://cedr.lbl.gov/icd9.html Accessed November 19, 2002.
78. Jacobson DL, Gange SJ, Rose NR, et al. Epidemiology and estimated population burden of elected autoimmune diseases in the United States. Clin Immunol Immunopathology. 1997;84:223-243.
79. Schuma AA. Autoimmune rheumatic diseases in women. J Am Pharm Assoc. 2002;42:612-624.
80. Lambert NC, Stevens AM, Tylee TS, et al. From the simple detection of microchimerism in patients with autoimmune diseases to its implication in pathogenesis. Ann NY Acad Sci. 2001;945:164-171.
81. Castagnetta L, Granata OM, Traina H, et al. A role for sex steroids in autoimmune diseases: A working hypothesis and supporting data. Ann NY Acad Sci. 2002;966:193-203.
82. Czaja AJ. Autoimmune hepatitis. Best Practice of Medicine. Available at: http://merck.praxis.md. Accessed November 5, 2002.
83. Hay JW, Hay AR. Inflammatory bowel disease: Costs-of-illness. J Clin Gastroenterol. 1992;14:309-317.
84. Wesierska-Gadek J, Reinisch W, Penner E. Autoimmunity of the gastrointestinal tract. In: Lahita RG ed. Textbook of the Autoimmune Diseases. Philadelphia, Pa: Lippincott Williams & Wilkins; 2002;229-272.
85. Calkins BM, Mendeloff AI. Epidemiology of inflammatory bowel disease. Epidemiology Rev. 1986;8:60-91.
86. Cotch MF. The socioeconomic impact of vasculitis. Curr Opin Rheumatol. 2000;12:20-23.
87. Anderson DW, Ellenberg JH, Leventhal CM, et al. Revised estimate of the prevalence of multiple sclerosis in the United States. Ann Neurol. 1992;31:333-6.
88. Brenitz EA, Strom BL. Epidemiology of sarcoidosis. Epidemiol Rev. 1983;5:124-156.
89. Javitz HS, Ward MM, Farber E, et al. The direct cost of care for psoriasis and psoriatic arthritis in the United States. J Am Acad Dermatol. 2002;46:850-860.
90. Taylor WJ. Epidemiology of psoriatic arthritis. Curr Opin Rheumatol. 2002;14:98-103.
91. Ward MM. Functional disability predicts total costs in patients with ankylosing spondylitis. Arthritis Rheum. 2002;46:223-231.
92. Khan MA. Update on spondyloarthropathies. Ann Intern Med. 2002; 136:896-907.
93. Fessel WJ. Systemic lupus erythematosus in the community. Arch Intern Med. 1974;134:1027-1035.
94. Wilson L. Cost-of-illness of scleroderma: The case for rare diseases. Semin Arthritis Rheum. 1997;27:73-84.
95. Eisenberg JM, Schulman KA, Glick H, et al. Pharmacoeconomics: Economic evaluation of pharmaceuticals. In: Strom B, ed. Pharmacoepidemiology. New York, NY: John Wiley & Sons; 1994;469-505.
96. Cooper MJ. Economic burden of rheumatoid arthritis: A systematic review. Rheumatology. 2000;39:28-33.
97. Bureau of Labor Statistics. Consumer price index - Revised seasonal factors and seasonally adjusted indexes, January 1987 - December 2001. Available at: http://ftp.bls.gov/pub/special.requests/cpi/revseas_2001 cpi.txt Accessed August 14, 2002.
98. Feagan BG, Vreeland MG, Larson LR, et al. Annual cost of care for Crohn's disease: A payor perspective. Am J Gastroenterol. 2000; 95:1955-1960.
99. Ward FM, Bodger K, Daly MJ, et al. Clinical economics review: Medical management of inflammatory bowel disease. Aliment Pharmacol Ther. 1999;13:15-25.
100. Silverstein MD, Loftus EV, Jr, Sandborn WJ, et al. Clinical course and costs of care for Crohn's disease: Markov model analysis of a population-based cohort. Gastroenterology. 1999;117:49-57.
101. Amin SP, Mullins CD, Duncan BS, et al. Direct health care costs for treatment of diabetes mellitus and hypertension in an IPA-group-model HMO. Am J Health Sys Pharm. 1999;56:1515-1520.
102. Whetten-Goldstein K, Sloan FA, Goldstein LB, et al. A comprehensive assessment of the cost of multiple sclerosis in the United States. Multiple Sclerosis. 1998;4:419-425.
103. Lubeck DP. A review of the direct costs of rheumatoid arthritis. Pharmacoeconomics. 2001;19:811-818.
104. Ward MM. Health services in rheumatology. Curr Opin Rheumatol. 2000;12:99-103.
105. Yelin H. The costs of rheumatoid arthritis: Absolute, incremental, and marginal estimates. J Rheumatol. 1996;23:(suppl 44)47-51.
106. Wong JB, Ramey DR, Singh G. Long-term morbidity, mortality, and economics of rheumatoid arthritis. Arthritis Rheum. 2001;44:2746-2749.
107. Newhall-Perry K, Law NJ, Ramos B, et al. Direct and indirect costs associated with the onset of seropositive rheumatoid arthritis. J Rheumatol. 2000;27:1156-1163.
108. Gironimi G, Clarke AE, Hamilton VH, et al. Comparing health care expenditures between systemic lupus erythematosus patients in Stanford and Montreal. Arthritis Rheum. 1996;39:979-987.
109. Clarke AE, Petri MA, Manzi S, et al. An international perspective on the well being and health care costs for patients with systemic lupus erythematosus. Tri-Nation Study Group. J Rheumatol. 1999;26:1500-11.
110. Doran MF, Pond GR, Crowson CS, et al. Trends in incidence and mortality in rheumatoid arthritis in Rochester, Minnesota, over a forty-year period. Arthritis Rheum. 2002;46;625-631.
111. Silman AJ. The changing face of rheumatoid arthritis: Why the decline in incidence? Arthritis Rheum. 2002;46;579-581.
112. Montonegro-Torres BF, Engelhardt T, Thamer M, et al. Are Fortune 100 companies responsive to chronically ill workers? Health Aff. 2001;20:209-219.
113. Neeck G. Fifty years of experience with cortisone therapy in the study and treatment of rheumatoid arthritis. Ann NY Acad Sci. 2002;966:28-38.
114. Van Vollenhoven RF. Corticosteroids in rheumatic disease: Understanding their effects is key to their use. Postgrad Med. 1998;103:137-142.
115. Podolsky N. Inflammatory bowel disease. N Engl J Med. 2002; 347:417-429.
116. Noseworthy JH, Lucchinetti C, Rodriguez M, et al. Multiple sclerosis. N Engl J Med. 2000; 343:938-952.
117. Rutgeerts PJ. Review article: The limitations of corticosteroid therapy in Crohn's disease. Aliment Pharmacol Ther. 2001;15:1515-1525.
118. Rakel RE, Bope ET, eds. Conn's Current Therapy 2002. Philadelphia, Pa: WB Saunders; 2002.
119. Williams RO, Feldmann M, Maini RN. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci USA. 1992;89:9784-9788.
120. Elliot MJ, Maini RN, Feldmann M, et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum. 1993;36:1681-1690.
121. Maini RN, Breedveld FC, Kalden JR, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. 1998:41:1552-1563.
122. Lipsky PE, Van Del Heijde DMFM, St, Clair EE, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med. 2000;343:1594-1602.
123. Targan SR, Hanauer SB, Deventer SJH, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor a for Crohn's disease. N Engl J Med. 1997;337:1029-1035.
124. Rutgeerts P, D'Haens G, Targan S, et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology. 1999;117:761-769.
125. Maksymowych WP, Jhangri GS, Lambert RG, et al. Infliximab in ankylosing spondylitis: A prospective observational inception cohort analysis of efficacy and safety. J Rheumatol. 2002;29:959-965.
126. Yee AMF, Pochapin MB. Treatment of complicated sarcoidosis with infliximab: Anti-tumor necrosis factor-a-therapy. Ann Intern Med. 2001;135:27-31.
127. Airo P, Antonioli CM, Vianelli M, et al. Anti-tumour necrosis factor treatment with infliximab in a case of giant cell arteritis resistant to steroid and immunosuppressive drugs. Rheumatology. 2002;41:347-349.
128. Moreland LW, Baumgartner SW, Schiff MH, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med. 1997;337:141-147.
129. Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med. 1999;340:253-259.
130. ACR definition of improvement in RA trials. Available at: www.hopkins-arthritis.som.jhmi.edu. Accessed August 11, 2002.
131. Lovell DJ, Giannini EH, Reiff A, et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. N Engl J Med. 2000;342:763-769.
132. Mease PJ, Goffe BS, Metz J, et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: A randomized trial. Lancet. 2000;356:385-390.
133. Gorman JD, Sack KE, Davis JC. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med. 2002;346:1349-1356.
134. Cada DJ, Levien T, Baker DE. Anakinra. Hospital Pharmacy. 2002;37:619-629.
135. Breshnihan B, Alvaro-Gracia JM, Cobby M, et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum. 1998;41:2196-2204.
136. Nashan B, Moore R, Amlot P, et al. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group. Lancet. 1997;350:1193-1198.
137. Vincenti F, Kirkman R, Light S, et al. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. N Engl J Med. 1998;338:161-165.
138. Cope AP. Regulation of autoimmunity by proinflammatory cytokines. Curr Opin Immunol. 1998;10:669-676.
139. Shakoor N, Michalska M, Harris CA, et al. Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet. 2002;359:579-581.
140. Charles PJ, Smeenk RJT, DeJong J, et al. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor α. Arthritis Rheum. 2000;43:2383-2390.
141. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor a-neutralizing agent. N Engl J Med. 2001;345:1098-1104.
142. Shaible TF. Long term safety of infliximab. Can J Gastroenterol. 2001;14(suppl):29C-32C.
143. Fleischmann R, Iqbal I, Nandeshwar P, et al. Safety and efficacy of disease-modifying anti-rheumatic agents: Focus on the benefits and risks of etanercept. Drug Safety. 2002;25:173-197.
144. Reichert JM. Monoclonal antibodies in the clinic. Nat Biotechnol. 2001;19:819-822.
145. Available at: http:/www.bioportfolio.com/news/btech_030402_4.htm. Accessed August 5, 2002.
146. Lorenz HM. Technology evaluation: Adalimumab, Abbott laboratories. Current Opinion Mol Ther. 2002;41:185-190.
147. Biogen announces results from CDP 571 studies in Crohn's disease. Biogenetics. July 30, 2002.
148. First Phase III data for Abbott Laboratories' D2E7 (Adalimumab) support promise in Rheumatoid Arthritis (RA). Abbott Laboratories. June 14, 2002.
149. Cambridge antibody technology interim results for the six months ended 31 March 2002. Cambridge Antibody Techn. May 20, 2002.
150. Dinan HJ, Dijkmans BA. New therapeutic targets for rheumatoid arthritis. Pharma World Sci. 1999;21:49-59.
151. Celltech group plc - CIBC conference call. CIBC. September 10, 2001.
152. Crawford J. Clinical uses of pegylated pharmaceuticals in oncology. Cancer Treat Rev. 2002;28(suppl A):7-11.
153. Positive data presented at major medical meeting on two drugs in Amgen's pipeline. Amgen. November 12, 2001.